Mesirow Institutional Investment Management, Inc. Halozyme Therapeutics, Inc. Transaction History
Mesirow Institutional Investment Management, Inc.
- $1.09 Billion
- Q2 2024
A detailed history of Mesirow Institutional Investment Management, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mesirow Institutional Investment Management, Inc. holds 289,805 shares of HALO stock, worth $16.5 Million. This represents 1.39% of its overall portfolio holdings.
Number of Shares
289,805
Previous 364,047
20.39%
Holding current value
$16.5 Million
Previous $14.8 Million
2.46%
% of portfolio
1.39%
Previous 1.38%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
488Shares Held
122MCall Options Held
208KPut Options Held
66.3K-
Black Rock Inc. New York, NY17.6MShares$1 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$733 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$331 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$230 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$212 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.93B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...